OPGN logo

OpGen, Inc. (OPGN)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

OPGN steht fuer OpGen, Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 63/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 16. März 2026
63/100 KI-Bewertung

OpGen, Inc. (OPGN) Gesundheitswesen & Pipeline-Uebersicht

CEOChristian-Laurent Benoit Bonte
Mitarbeiter85
HauptsitzRockville, US
IPO-Jahr2015

OpGen, Inc. specializes in molecular microbiology solutions, offering diagnostic tools like the Acuitas AMR Gene Panel and Unyvero Platform. These technologies assist clinicians in identifying pathogens and antimicrobial resistance, contributing to improved patient outcomes and infection control within the healthcare sector. The company operates in the United States and internationally.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 16. März 2026

Investmentthese

OpGen, Inc. presents a notable research candidate within the precision medicine and molecular diagnostics space. The company's focus on combating antimicrobial resistance (AMR) aligns with a growing global health concern. Key value drivers include the increasing adoption of OpGen's Acuitas AMR Gene Panel and Unyvero Platform, driven by the need for rapid and accurate detection of AMR genes and pathogens. The collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, provides a platform for further research and development in antimicrobial resistance management. However, potential risks include competition from established players in the diagnostics market and the need for continued innovation to maintain a competitive edge. With a market capitalization of $0.25 billion and a profit margin of 76.0%, OpGen demonstrates financial stability and growth potential.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $0.25 billion indicates the company's current valuation in the market.
  • A P/E ratio of 36.43 suggests investors are willing to pay a premium for each dollar of earnings, reflecting growth expectations.
  • Profit margin of 76.0% demonstrates strong profitability and efficient operations.
  • Gross margin of 98.9% indicates effective cost management in the production of diagnostic solutions.
  • Beta of -1.93 suggests the stock price moves inversely to the market, potentially offering diversification benefits.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Proprietary ARES Technology Platform for antimicrobial resistance prediction.
  • Comprehensive Unyvero Platform for automated molecular diagnostics.
  • Collaboration with New York State Department of Health and ILÚM Health Solutions, LLC.
  • Strong gross margin of 98.9%.

Schwaechen

  • Limited market presence compared to larger diagnostic companies.
  • Reliance on a small number of key products.
  • OTC market listing may limit access to capital.
  • Beta of -1.93 indicates high volatility.

Katalysatoren

  • Ongoing: Increasing adoption of Acuitas AMR Gene Panel due to rising antimicrobial resistance.
  • Ongoing: Expansion of ARES Technology Platform capabilities and database.
  • Upcoming: Potential new partnerships with healthcare institutions for research and development.
  • Upcoming: Possible expansion into new international markets.
  • Ongoing: Continued development of novel diagnostic assays for emerging infectious diseases.

Risiken

  • Potential: Competition from established diagnostic companies with greater resources.
  • Potential: Regulatory changes affecting the approval and reimbursement of diagnostic tests.
  • Potential: Technological advancements rendering existing products obsolete.
  • Ongoing: Limited market presence compared to larger competitors.
  • Ongoing: OTC market listing may limit access to capital and investor confidence.

Wachstumschancen

  • Expansion of Acuitas AMR Gene Panel adoption: The increasing global threat of antimicrobial resistance (AMR) drives the demand for rapid and accurate diagnostic tools. OpGen's Acuitas AMR Gene Panel offers a solution for detecting and identifying bacterial nucleic acids and genetic determinants of AMR. The market for AMR diagnostics is projected to reach $4.5 billion by 2028, presenting a significant growth opportunity for OpGen. Timeline: Ongoing.
  • Leveraging the ARES Technology Platform: OpGen's ARES Technology Platform, with its comprehensive reference database and AI-powered bioinformatics, provides a competitive advantage in antibiotic response prediction. The platform can be expanded to include additional pathogens and resistance genes, broadening its applicability and market reach. The market for AI in drug discovery is expected to reach $2 billion by 2027. Timeline: Ongoing.
  • Strategic collaborations and partnerships: Collaborating with healthcare institutions and research organizations can accelerate the development and commercialization of OpGen's diagnostic solutions. The ongoing collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC, serves as a model for future partnerships. Such collaborations can provide access to valuable data, expertise, and funding. Timeline: Ongoing.
  • Geographic expansion into international markets: OpGen has the opportunity to expand its market presence beyond the United States by targeting international markets with a high prevalence of infectious diseases and AMR. This expansion can be achieved through strategic partnerships, distribution agreements, and direct sales efforts. The global market for molecular diagnostics is projected to reach $14 billion by 2025. Timeline: 2027-2030.
  • Development of novel diagnostic assays: Investing in research and development to create new diagnostic assays for emerging infectious diseases and antimicrobial resistance mechanisms can drive future growth. This includes exploring new technologies such as next-generation sequencing and CRISPR-based diagnostics. The market for novel diagnostic assays is constantly evolving, offering opportunities for innovation and market leadership. Timeline: 2028-2032.

Chancen

  • Expansion of Acuitas AMR Gene Panel adoption in response to increasing antimicrobial resistance.
  • Geographic expansion into international markets.
  • Development of novel diagnostic assays for emerging infectious diseases.
  • Strategic partnerships with healthcare institutions and research organizations.

Risiken

  • Competition from established diagnostic companies.
  • Regulatory changes affecting the approval and reimbursement of diagnostic tests.
  • Technological advancements rendering existing products obsolete.
  • Economic downturn impacting healthcare spending.

Wettbewerbsvorteile

  • Proprietary ARES Technology Platform with extensive antimicrobial resistance database.
  • Established relationships with key healthcare institutions and research organizations.
  • Unyvero platform provides a comprehensive solution for molecular diagnostics.
  • Expertise in molecular microbiology and infectious disease diagnostics.

Ueber OPGN

OpGen, Inc., established in 2001 and headquartered in Rockville, Maryland, is a precision medicine company dedicated to developing and commercializing molecular microbiology solutions. The company's mission is to combat infectious diseases by providing clinicians with advanced diagnostic tools and information to enhance patient outcomes and reduce the spread of multidrug-resistant microorganisms. OpGen's product portfolio includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed for the detection and identification of bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies. This technology enables rapid and accurate identification of resistance genes, aiding in the selection of appropriate antibiotic therapies. Additionally, OpGen offers Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The ARES Technology Platform is another key offering, featuring a comprehensive reference database on antimicrobial resistance using next-generation sequencing technology and artificial intelligence-powered bioinformatics solutions for antibiotic response prediction. The Unyvero Platform, an automated sample-to-answer molecular diagnostics platform, integrates automated sample preparation, analysis, and identification of disease-relevant pathogens and antibiotic resistance markers. OpGen collaborates with the New York State Department of Health and ILÚM Health Solutions, LLC, to develop a research program focused on detecting, tracking, and managing antimicrobial-resistant infections within healthcare institutions.

Was das Unternehmen tut

  • Develop and commercialize molecular microbiology solutions.
  • Offer the Acuitas AMR Gene Panel for detecting antimicrobial resistance.
  • Provide Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
  • Utilize the ARES Technology Platform for antibiotic response prediction.
  • Offer the Unyvero Platform for automated molecular diagnostics.
  • Help clinicians with information about life-threatening infections.
  • Decrease the spread of infections caused by multidrug-resistant microorganisms.

Geschaeftsmodell

  • Sales of diagnostic kits and platforms (Acuitas AMR Gene Panel, Unyvero Platform).
  • Licensing of ARES Technology Platform and related intellectual property.
  • Collaborative research and development agreements with healthcare institutions.
  • Service contracts for maintenance and support of diagnostic equipment.

Branchenkontext

OpGen operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in molecular biology and the increasing prevalence of infectious diseases. The market for antimicrobial resistance (AMR) diagnostics is expanding due to the urgent need for rapid and accurate detection of resistant pathogens. Competition includes established diagnostic companies and emerging players offering innovative solutions. OpGen's focus on precision medicine and its comprehensive product portfolio position it to capitalize on the growing demand for advanced diagnostic tools in healthcare.

Wichtige Kunden

  • Hospitals and healthcare systems.
  • Clinical microbiology laboratories.
  • Research institutions and universities.
  • Public health organizations.
KI-Zuversicht: 72% Aktualisiert: 16. März 2026

Finanzdaten

Chart & Info

OpGen, Inc. (OPGN) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer OPGN.

Kursziele

Wall-Street-Kurszielanalyse fuer OPGN.

MoonshotScore

63/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von OPGN auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Klassifizierung

Sektor Healthcare Branche Medical - Diagnostics & Research

Wettbewerber & Vergleichsunternehmen

Aktuelle Nachrichten

Fuehrung: Christian-Laurent Benoit Bonte

CEO

Christian-Laurent Benoit Bonte serves as the CEO of OpGen, Inc. He has extensive experience in the healthcare and diagnostics industries, with a background in leading and managing teams. His expertise includes strategic planning, business development, and commercialization of medical technologies. Bonte's previous roles have equipped him with a deep understanding of the challenges and opportunities in the precision medicine space. He is responsible for overseeing the company's overall strategy and operations.

Erfolgsbilanz: Under Christian-Laurent Benoit Bonte's leadership, OpGen, Inc. has focused on expanding its product portfolio and strengthening its market position in the molecular microbiology diagnostics sector. Key achievements include the continued development and commercialization of the Acuitas AMR Gene Panel and the Unyvero Platform. Bonte has also overseen strategic collaborations aimed at advancing research and development in antimicrobial resistance management.

OPGN OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that OpGen, Inc. may not meet the minimum financial or regulatory requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited reporting requirements and may be subject to greater risks due to less stringent oversight. Trading on the OTC Other tier can result from various factors, including financial distress, regulatory non-compliance, or strategic decisions by the company. Compared to NYSE/NASDAQ, the OTC Other tier offers significantly less transparency and regulatory protection for investors.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity on the OTC market for OpGen, Inc. is likely to be limited, potentially resulting in wider bid-ask spreads and greater price volatility. The trading volume may be lower compared to stocks listed on major exchanges, making it more difficult to buy or sell large quantities of shares without significantly impacting the price. Investors should exercise caution and consider the potential for illiquidity when trading OPGN on the OTC market.
OTC-Risikofaktoren:
  • Limited regulatory oversight and disclosure requirements.
  • Potential for lower trading volume and liquidity.
  • Increased price volatility and wider bid-ask spreads.
  • Higher risk of fraud or manipulation compared to listed exchanges.
  • Difficulty in obtaining accurate and timely financial information.
Sorgfaltspruefung-Checkliste:
  • Verify the company's financial statements and regulatory filings.
  • Assess the company's management team and their track record.
  • Evaluate the company's business model and competitive landscape.
  • Review the company's risk factors and potential liabilities.
  • Check for any legal or regulatory issues involving the company.
  • Monitor the company's news and press releases for updates.
  • Consult with a qualified financial advisor before investing.
Legitimitaetssignale:
  • Established business operations since 2001.
  • Focus on precision medicine and molecular microbiology solutions.
  • Collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC.
  • Development of proprietary technologies such as the ARES Technology Platform.
  • Presence of a CEO with experience in the healthcare and diagnostics industries.

Haeufige Fragen zu OPGN

What are the key factors to evaluate for OPGN?

OpGen, Inc. (OPGN) currently holds an AI score of 63/100, indicating moderate score. Key strength: Proprietary ARES Technology Platform for antimicrobial resistance prediction.. Primary risk to monitor: Potential: Competition from established diagnostic companies with greater resources.. This is not financial advice.

How frequently does OPGN data refresh on this page?

OPGN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven OPGN's recent stock price performance?

Recent price movement in OpGen, Inc. (OPGN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary ARES Technology Platform for antimicrobial resistance prediction.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider OPGN overvalued or undervalued right now?

Determining whether OpGen, Inc. (OPGN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying OPGN?

Before investing in OpGen, Inc. (OPGN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding OPGN to a portfolio?

Potential reasons to consider OpGen, Inc. (OPGN) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary ARES Technology Platform for antimicrobial resistance prediction.. Additionally: Comprehensive Unyvero Platform for automated molecular diagnostics.. The AI-driven MoonshotScore of 63/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of OPGN?

Yes, most major brokerages offer fractional shares of OpGen, Inc. (OPGN) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track OPGN's earnings and financial reports?

OpGen, Inc. (OPGN) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for OPGN earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Information is based on available sources and may be subject to change.
  • AI analysis is pending for OPGN stock.
Datenquellen

Popular Stocks